OneSource Specialty Pharma, a company formed from the merger of three CDMOs within the Strides Group, has launched at CPHI Milan.
The company, which has a 30 years of experience in the manufacture of pharmaceuticals, gelatin capsules and drug-device combinations, will be on hand at stand 5C33 to discuss with potential collaborators.
With the exceptional growth of GLP-1s in the pharmaceutical market currently, as well as the BIOSECURE Act, OneSource is addressing the increased demand for drug-device combiations.
The company will achieve this through the utilisation of its five facilities, which are all approved by major regulatory boards, such as the FDA, EU and TGA.
With its current capabilities, OneSource can produce more than 100m injectable doses per year — including pre-filled syringes and cartridges.
As well as this, the company has the capacity to produce 2.4bn soft gelatin capsules per year.
OneSource's flagship Bangalore facility is also one of the few manufacturing sites globally than is capable of manufacturing both biologic drug substances and drug products.
End-to-end services for streamlined manufacturing
OneSource's three combined businesses currently serve more than 50 global clients, and together reduce the complexity and cost of collaborating with multiple CDMO service providers — while also reducing the amount of resources necessary for pharmaceutical production.
The CDMO is currently projected to achieve a growth in revenue of 32% by 2025, with sales expected to reach USD $400m by 2028.
OneSource's CEO, Neeraj Sharma, commented: “Our vision is to blend the expertise of global CDMO giants with the agility and service levels of a challenger, all supported by our unwavering commitment to bring the most efficient and quality products to our partners."
"As demand for innovative CDMO solutions grows, especially for complex therapies, we are well-positioned to accelerate drug development and manufacturing for our global partners. We’re excited to participate in CPHI Milan and look forward to forging new partnerships.”
OneSource is currently undergoing regulatory approvals and, upon completion, will be listed on the India stock exchanges. Visit OneSource Pharma at CPHI Milan [stand 5C33].
